Skip to main content
. Author manuscript; available in PMC: 2020 Dec 12.
Published in final edited form as: N Engl J Med. 2019 Oct 20;381(24):2304–2314. doi: 10.1056/NEJMoa1908142

Figure 2. Exacerbations of Chronic Obstructive Pulmonary Disease (COPD).

Figure 2.

Panel A shows the Kaplan-Meier estimate of freedom from exacerbation of COPD in the two trial groups. The median time until the first exacerbation was 202 days in the metoprolol group and 222 days in the placebo group. Panel B shows the probability of freedom from either a severe exacerbation (leading to hospitalization) or a very severe exacerbation (leading to hospitalization with intubation and mechanical ventilation). Severe or very severe exacerbations occurred in 26.1% of the patients in the metoprolol group and in 14.8% of those in the placebo group.